Insufficient scRNA-seq data for expression of OPRL1 at single-cell level.
Insufficient scRNA-seq data for expression of OPRL1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 961.07 | 2574 / 2642 | 29% | 0.46 | 206 / 705 |
spleen | 100% | 699.17 | 241 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 87% | 209.62 | 224 / 258 | 10% | 0.16 | 22 / 230 |
lung | 91% | 224.85 | 524 / 578 | 1% | 0.02 | 14 / 1155 |
peripheral blood | 87% | 1208.41 | 807 / 929 | 0% | 0 | 0 / 0 |
breast | 79% | 156.17 | 364 / 459 | 6% | 0.11 | 69 / 1118 |
adipose | 75% | 141.73 | 908 / 1204 | 0% | 0 | 0 / 0 |
prostate | 74% | 150.55 | 182 / 245 | 0% | 0 | 0 / 502 |
pancreas | 63% | 117.38 | 205 / 328 | 0% | 0 | 0 / 178 |
blood vessel | 59% | 104.50 | 788 / 1335 | 0% | 0 | 0 / 0 |
thymus | 47% | 72.52 | 309 / 653 | 0% | 0.00 | 1 / 605 |
intestine | 44% | 86.07 | 426 / 966 | 0% | 0.00 | 2 / 527 |
bladder | 38% | 56.76 | 8 / 21 | 2% | 0.03 | 9 / 504 |
uterus | 35% | 63.91 | 59 / 170 | 2% | 0.04 | 9 / 459 |
skin | 23% | 33.01 | 419 / 1809 | 9% | 0.12 | 41 / 472 |
kidney | 30% | 48.37 | 27 / 89 | 0% | 0.00 | 1 / 901 |
heart | 26% | 39.06 | 220 / 861 | 0% | 0 | 0 / 0 |
stomach | 22% | 31.76 | 80 / 359 | 1% | 0.07 | 3 / 286 |
ovary | 14% | 22.34 | 25 / 180 | 5% | 0.07 | 20 / 430 |
esophagus | 15% | 21.87 | 222 / 1445 | 1% | 0.01 | 1 / 183 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.05 | 1 / 29 |
liver | 3% | 4.60 | 6 / 226 | 0% | 0 | 0 / 406 |
eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
muscle | 1% | 1.26 | 7 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019233 | Biological process | sensory perception of pain |
GO_0044849 | Biological process | estrous cycle |
GO_0032355 | Biological process | response to estradiol |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_1990708 | Biological process | conditioned place preference |
GO_0019722 | Biological process | calcium-mediated signaling |
GO_0007600 | Biological process | sensory perception |
GO_1904059 | Biological process | regulation of locomotor rhythm |
GO_0045776 | Biological process | negative regulation of blood pressure |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0042755 | Biological process | eating behavior |
GO_0043951 | Biological process | negative regulation of cAMP-mediated signaling |
GO_0106072 | Biological process | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0038003 | Biological process | G protein-coupled opioid receptor signaling pathway |
GO_0035810 | Biological process | positive regulation of urine volume |
GO_0005886 | Cellular component | plasma membrane |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0043005 | Cellular component | neuron projection |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0042923 | Molecular function | neuropeptide binding |
GO_0001626 | Molecular function | nociceptin receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | OPRL1 |
Protein name | Nociceptin receptor (Kappa-type 3 opioid receptor) (KOR-3) (Orphanin FQ receptor) Nociceptin receptor (Kappa-type 3 opioid receptor) (Orphanin FQ receptor) |
Synonyms | NOP OOR ORL1 KOR3 OPRL |
Description | FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin. . |
Accessions | ENST00000625570.1 ENST00000672146.3 A0A6H0W9J6 Q6FGM5 ENST00000336866.7 [P41146-1] ENST00000615600.3 A0A0G2JQE4 A0A5F9ZI64 P41146 A0A6H0WF25 ENST00000627060.2 A0A6H0WB77 ENST00000349451.3 [P41146-1] ENST00000355631.8 [P41146-1] |